Global Human Recombinant Insulin Market: Restraint
The major factors that hinder the growth of the global human recombinant insulin market include high cost of insulin, as patients from low and middle countries are unable to afford it. For instance, in September 2020, an article published by the Office of the Assistant Secretary for Planning and Evaluation (ASPE) at the U.S. Department of Health & Services compared insulin, pricing in the U. S. and in other countries showed that in 2018, the average gross manufacturer price for a normal unit of insulin was more than ten times the price in a sample of 32 foreign countries price of insulin in the U.S were US$ 98.70 and US$ 8.81 in the 32 Non-U.S. the Organization for Economic Co-operation and Development (OECD) countries.
Human Recombinant Insulin Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients